Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 08 04:00PM ET
0.3498
Dollar change
-0.0001
Percentage change
-0.03
%
Index- P/E- EPS (ttm)-16.05 Insider Own6.26% Shs Outstand2.59M Perf Week-0.99%
Market Cap0.91M Forward P/E- EPS next Y-1.65 Insider Trans0.00% Shs Float2.43M Perf Month-24.77%
Income-26.14M PEG- EPS next Q-2.73 Inst Own10.46% Short Float10.07% Perf Quarter-81.09%
Sales0.00M P/S- EPS this Y75.40% Inst Trans- Short Ratio0.53 Perf Half Y-88.61%
Book/sh1.70 P/B0.21 EPS next Y70.27% ROA-232.21% Short Interest0.24M Perf Year-97.52%
Cash/sh0.95 P/C0.37 EPS next 5Y- ROE-318.88% 52W Range0.28 - 15.20 Perf YTD-96.20%
Dividend Est.- P/FCF- EPS past 5Y8.89% ROI-601.59% 52W High-97.70% Beta-0.57
Dividend TTM- Quick Ratio1.95 Sales past 5Y0.00% Gross Margin- 52W Low24.66% ATR (14)0.06
Dividend Ex-Date- Current Ratio1.95 EPS Y/Y TTM33.93% Oper. Margin0.00% RSI (14)27.94 Volatility10.50% 12.16%
Employees26 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.50
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q51.07% Payout- Rel Volume0.40 Prev Close0.35
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsAug 28 Avg Volume461.08K Price0.35
SMA20-6.80% SMA50-50.75% SMA200-89.16% Trades Volume182,368 Change-0.03%
Date Action Analyst Rating Change Price Target Change
Jan-26-21Initiated National Securities Buy $7
Apr-29-19Initiated Noble Capital Markets Outperform $5
Oct-07-24 09:29AM
Sep-23-24 09:29AM
Sep-19-24 09:29AM
Sep-09-24 09:29AM
Sep-04-24 09:29AM
08:15AM Loading…
Sep-03-24 08:15AM
Aug-15-24 09:30AM
Aug-14-24 09:25AM
Aug-13-24 08:31AM
Aug-08-24 08:30AM
Jun-27-24 08:31AM
May-30-24 08:31AM
May-20-24 12:53PM
May-15-24 04:42AM
May-14-24 08:31AM
08:31AM Loading…
May-13-24 08:31AM
May-08-24 06:08PM
May-07-24 09:15AM
May-01-24 08:31AM
Apr-09-24 08:31AM
Apr-04-24 08:57AM
Apr-03-24 08:31AM
Apr-02-24 08:31AM
Mar-22-24 04:10PM
Mar-19-24 01:24PM
Mar-12-24 09:01AM
Mar-06-24 08:30AM
Feb-07-24 08:15AM
Feb-06-24 07:30AM
Feb-05-24 07:30AM
08:42AM Loading…
Jan-31-24 08:42AM
Jan-05-24 07:00AM
Nov-23-23 08:30AM
Nov-03-23 09:00AM
Nov-01-23 07:30AM
Oct-20-23 03:00PM
07:30AM
Oct-06-23 09:00AM
Oct-04-23 12:00PM
Sep-21-23 08:30AM
Sep-19-23 09:00AM
Sep-08-23 08:00PM
Sep-07-23 07:30AM
Sep-04-23 12:00PM
Sep-01-23 09:20PM
Aug-31-23 12:44AM
Aug-24-23 12:25AM
Aug-23-23 02:06AM
Aug-22-23 07:30AM
Aug-13-23 10:24AM
Aug-10-23 07:30AM
Aug-08-23 01:04AM
Jul-28-23 08:00PM
Jul-25-23 01:22AM
Jul-21-23 04:15PM
12:57AM
Jul-20-23 01:05AM
Jul-19-23 08:00AM
12:37AM
Jul-18-23 08:37AM
Jul-12-23 01:00AM
Jul-07-23 09:00PM
Jul-06-23 08:17AM
12:51AM
Jul-05-23 08:35AM
Jun-29-23 09:03PM
Jun-28-23 08:35AM
Jun-02-23 10:15AM
Jun-01-23 11:59AM
May-31-23 12:59AM
May-30-23 07:30AM
May-26-23 06:00PM
May-25-23 05:00PM
May-23-23 07:30AM
May-09-23 07:15AM
May-08-23 07:30AM
May-02-23 03:30PM
Apr-19-23 09:11AM
Apr-18-23 09:11AM
Apr-03-23 06:12AM
Mar-23-23 07:30AM
Mar-13-23 07:30AM
Mar-08-23 07:30AM
Feb-27-23 08:30AM
Feb-23-23 07:00AM
Jan-05-23 07:00AM
Jan-04-23 07:00AM
Dec-15-22 07:00AM
Dec-14-22 07:00AM
Dec-02-22 08:15AM
Oct-24-22 09:45AM
Oct-07-22 07:45AM
Sep-08-22 08:15AM
Aug-16-22 07:00AM
Aug-15-22 07:00AM
Jul-13-22 07:00AM
Jun-02-22 07:00AM
May-19-22 08:15AM
May-17-22 08:23AM
May-09-22 08:15AM
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company's lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.